BUSINESS
Cess on imported medical devices to make healthcare costlier
With an additional 5% health cess, the new customs duty becomes 12.5 percent, this is in addition to the education cess levied on importers.
BUSINESS
Budget 2020 | Healthcare spending sees marginal rise, govt focuses on healthcare infra in small towns
Allocation for Ayushman Bharat scheme remained flat at Rs 6,400 crore.
BUSINESS
Budget 2020: Cess on imported medical devices fails to enthuse domestic manufacturers
“To give impetus to domestic industry, and to generate resource for health services, it is proposed to impose a nominal health cess of 5 percent on imports of specified medical equipment,” said Finance Minister Nirmala Sitharaman in her budget speech.
BUSINESS
Coronavirus outbreak: Indian drug makers may see disruption of drug supply chain in coming weeks
India imports about $4.5 billion worth of APIs and KSMs from China. These include antibiotics, hormones, vitamins, anti-hypertension and anti-diabetes drugs.
WORLD
Coronavirus update: No confirmed cases in India, Chinese top expert says outbreak may peak in 7-10 days
The Indian government said one suspected case in Jaipur, Rajasthan, had turned out to be negative.
BUSINESS
Budget 2020: A look at pharma sector's wishlist for FM Nirmala Sitharaman
The pharma companies are also hopes the government will announce incentives in the Budget to encourage setting up bulk drug manufacturing units in the country.
BUSINESS
Healthcare bodies IPA, IMA differ on media reports of doctors taking bribes
Earlier - the Indian Medical Association (IMA) - the body representing doctors in India, took a strong exception to the development.
BUSINESS
Exclusive | 10 years on: How govt's Rs 600cr vaccine complex failed to take-off
The government may be considering to bring in a partner in public-private partnership (PPP) mode to revive Rs 600 crore Integrated Vaccine Complex (IVC), at Chengalpattu
BUSINESS
Exclusive: Aurobindo Pharma promoters open new front in Continental Hosp founder vs IHH Healthcare fight
The Aurobindo family will fund gastroenterologist Gurunath Reddy buy out stake held by IHH Healthcare, and ring-fence Continental Hospitals from other prospective buyers.
BUSINESS
Here is why horse breeding is the secret behind success of Cyrus Poonawalla's vaccine business
With a net worth of $13 billion, Poonawalla is the fourth richest person in India and 100th in the world, according to Hurun Global Rich List - 2019.
BUSINESS
American PE firm's investment proposition to rich Indians: Assured returns, repayment guarantee and a EB-5 visa
With EB-5 opening up access to cheap long-term funds, US private equity and real estate firms are increasingly chasing investors in Asian countries such as China, India, Vietnam and South Korea.
BUSINESS
Top five discoveries in 2018 that can solve unmet medical needs
For those suffering from diabetes, pricking fingers may become a thing of the past very soon.
BUSINESS
Patients with faulty J&J hip implants may get up to Rs 1.22-crore compensation
There are currently no specific legal provisions in India to provide compensation to patients
BUSINESS
Exclusive: As polio threat looms, Indonesia's Bio Farma denies contamination of oral vaccine
Bio Farma has come under the lens of Indian drug regulator CDSCO as it supplied bulk vaccine or key starting material to Biomed.
BUSINESS
Fortis saga: Shivinder Singh moves NCLT against elder brother Malvinder
Shivinder said that he can no longer be party to activities in which transparency and ethics are continuously and consistently negated.
BUSINESS
Fortis board unanimously approves Rs 4,000 crore IHH Healthcare bid
Fortis' chairman Rajagopal believes that "the IHH proposal offers a more strategically and financially compelling proposition along with simplicity and certainty."
BUSINESS
Fortis calls off demerger of diagnostics arm, SRL, citing headwinds for the sector
Fortis had approved the demerger of SRL in August 2016 to unlock value of the diagnostic business and focus on its core hospital business
BUSINESS
Fortis defers Q4 results by 2 weeks, says it needs time to consider internal investigation report
Fortis' board did not disclose any details of the internal investigation report, but said it had shared the findings of Luthra & Luthra with the statutory auditors
BUSINESS
US gives nod to Biocon-Mylan's biosimilar of cancer drug Herceptin, revenues expected from FY19
Ogivri is the first FDA-approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon’s joint portfolio approved in the US
BUSINESS
Sun Pharma gets EIR for Dadra formulation facility
Dadra is the company’s second largest USFDA-approved plant after Halol with several pending generic filings. Analysts estimate the Dadra formulation plant to generate USD 250 million in annual sales.
BUSINESS
Mylan launches copy of Copaxone 40 mg even as patent litigation is on
The launch comes as analysts were debating whether Mylan would wait till the outcome of pending patent ligation or it will go ahead and launch “at risk”.
BUSINESS
Dr Reddy's gets two USFDA observations for Srikakulam plant
The company said was addressing the observations raised by US FDA without specifying the nature of those observations.
